Commitments and Contingencies (Details Textual)		1 Months Ended	3 Months Ended
	Sep. 03, 2014 USD ($) shares	Jan. 31, 2020 USD ($)	Mar. 31, 2020 USD ($) $ / shares shares	Dec. 31, 2019 USD ($) ft²
Commitments and Contingencies (Textual)
Commitments related to agreements				$ 475,000
Maximum payment for commitment milestones	$ 10,000,000		$ 7,900,000
Office lease amendment date			October 2017
Percentage for royalties			0.00%
Office rent amount, Nov. 1, 2019				$ 11,883
Office rent amount Nov. 1, 2019, per square foot			23.00
Cash paid to acquire Hy Biopharma intangible asset	$ 275,000
Shares issued in connection with Hy BioPharma asset purchase agreement | shares	184,912		5,000,000
Common stock price per share | $ / shares			$ 2.56
Fair value of shares issued in connection with Hy BioPharma asset purchase	$ 3,750,000		$ 1,956,182
Maximum percentage of Hy BioPharma ownership of Soligenix outstanding stock	19.90%
Office space | ft²				6,200
Maximum [Member]
Commitments and Contingencies (Textual)
Authorized shares to be issued to Dr. Schaber immediately prior to the completion of a transaction		$ 500,000
Minimum [Member]
Commitments and Contingencies (Textual)
Authorized shares to be issued to Dr. Schaber immediately prior to the completion of a transaction		$ 5,000